A- A A+

Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation. 

Brogdon H, Facer KL, Cox EJ, Carlson RH Jr, Wurzel JF 3rd. 

J Addict Med. 2021 Dec 3. doi: 10.1097/ADM.0000000000000935. Epub ahead of print. PMID: 34864786.



Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report. 

Hagan S, Achtmeyer CE, Hood C, Hawkins EJ, Williams EC. 

Addict Sci Clin Pract. 2021 Dec 3;16(1):71. doi: 10.1186/s13722-021-00280-4. PMID: 34861895; PMCID: PMC8641214.


Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program. 

Furo H, Schwartz DG, Sullivan RW, Elkin PL. 

Subst Abuse. 2021 Dec 6;15:11782218211061749. doi: 10.1177/11782218211061749. PMID: 34898987; PMCID: PMC8655441.


Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. 

Soyka M. 

Front Pharmacol. 2021 Nov 23;12:718811. doi: 10.3389/fphar.2021.718811. PMID: 34887748; PMCID: PMC8650116.


"I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design). 

Shepherd K, Pritty B, Tickle A, Moghaddam N. 

Int J Ment Health Addict. 2021 Dec 20:1-24. doi: 10.1007/s11469-021-00729-2. Epub ahead of print. PMID: 34955695; PMCID: PMC8686789.


Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 

AUDIENCE: Dentistry, Anesthesiology, Patient, Health Professional, Pharmacy

ISSUE: The FDA is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks. (FDA – U.S. Food and Drug Administration, USA, 12.01.2022)


Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. 

Somaini L, Vecchio S, Corte C, Coppola C, Mahony A, Pitts A, Cutuli M, Orso R, Littlewood R. 

Cureus. 2021 Oct 5;13(10):e18513. doi: 10.7759/cureus.18513. PMID: 34754672; PMCID: PMC8568308.


Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report. 

Menard S, Jhawar A. 

Ment Health Clin. 2021 Nov 8;11(6):369-372. doi: 10.9740/mhc.2021.11.369. PMID: 34824962; PMCID: PMC8582770.


Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine. 

Stein MD, VanNoppen D, Herman DS, Anderson BJ, Conti M, Bailey GL. 

J Subst Abuse Treat. 2021 Nov 14:108661. doi: 10.1016/j.jsat.2021.108661. Epub ahead of print. PMID: 34801283.



Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. 

Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L; CoLAB study team. 

Int J Drug Policy. 2021 Nov 1;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub ahead of print. PMID: 34736130.


Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 

Roache, J.D., Pavlicova, M., Campbell, A., Choo, T.-H., Peavy, M., Kermack, A.S., Nunes, E.V., Jr. and Rotrosen, J. (2021), 

Alcoholism: Clinical and Experimental Research. Accepted Author Manuscript. doi.org/10.1111/acer.14729


Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. 

Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L; CoLAB study team. 

Int J Drug Policy. 2021 Nov 1;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub ahead of print. PMID: 34736130.


Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. 

Soyka M, Franke AG. 

World J Psychiatry. 2021 Sep 19;11(9):543-552. doi: 10.5498/wjp.v11.i9.543. PMID: 34631459; PMCID: PMC8474991.


Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US. 

Han B, Jones CM, Einstein EB, Compton WM. 

JAMA Netw Open. 2021;4(10):e2129409. doi:10.1001/jamanetworkopen.2021.29409


Recovery capital among people receiving treatment for opioid use disorder with buprenorphine. 

Parlier-Ahmad, A.B., Terplan, M., Svikis, D.S. et al.

Harm Reduct J 18, 103 (2021). doi.org/10.1186/s12954-021-00553-w


Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder? 

Kessler SH, Schwarz ES, Liss DB. 

J Med Toxicol. 2021 Sep 23. doi: 10.1007/s13181-021-00858-z. Epub ahead of print. PMID: 34554396.



A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets. 

Modak T, Sarkar S, Balhara YPS. 

J Opioid Manag. 2021;17(7):141-152. doi: 10.5055/jom.2021.0651. PMID: 34520035.



A cross-sectional survey on buprenorphine-naloxone practice and attitudes in 22 Canadian emergency physician groups: a cross-sectional survey. 

Kestler A, Kaczorowski J, Dong K, Orkin AM, Daoust R, Moe J, Van Pelt K, Andolfatto G, Klaiman M, Yan J, Koh JJ, Crowder K, Webster D, Atkinson P, Savage D, Stempien J, Besserer F, Wale J, Lam A, Scheueremeyer F. 

CMAJ Open. 2021 Sep 21;9(3):E864-E873. doi: 10.9778/cmajo.20200190. Erratum in: CMAJ Open. 2021 Oct 5;9(4):E928. PMID: 34548331; PMCID: PMC8476213.


Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail. 

Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, Garment A, Porter B, Goldfeld KS, Matteo M, Mangat J, Katyal M, Giftos J, MacDonald R. 

JAMA Netw Open. 2021 Sep 1;4(9):e2123032. doi: 10.1001/jamanetworkopen.2021.23032. PMID: 34495340; PMCID: PMC8427378.


Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan. 

Nagano T, Kimoto S, Aso K, Komori T, Yamaguchi Y, Okamura K, Yamamoto N, Kishimoto T. 

Neuropsychopharmacol Rep. 2020 Dec;40(4):376-382. doi: 10.1002/npr2.12147. Epub 2020 Oct 27. PMID: 33107693; PMCID: PMC7722651.


Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel

Kohan L, Potru S, Barreveld AM, et al

Regional Anesthesia & Pain Medicine 2021;46:840-859.


Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. 

Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. 

JAMA Netw Open. 2021;4(9):e2123019. doi:10.1001/jamanetworkopen.2021.23019


Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 

Lintzeris N, Dunlop A, Masters D (2019) 

NSW Ministry of Health, Sydney Australia


Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. 

Soyka M, Groß G. Am J Drug Alcohol Abuse. 2021 Aug 18:1-6. doi: 10.1080/00952990.2021.1963757. Epub ahead of print. PMID: 34407703.


Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder. 

Schellekens AFA, Veldman SE, Suranto ESD, van Rijswijk SM, van der Wal SEI, Schene AH, van Beek MHCT. 

J Clin Med. 2021 Aug 21;10(16):3727. doi: 10.3390/jcm10163727. PMID: 34442024; PMCID: PMC8396821.


Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. 

Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ, Haber P, Graham R, Hayes V, Lubman DI.

Drug Alcohol Depend. 2021 Aug 11;227:108959. doi: 10.1016/j.drugalcdep.2021.108959. Epub ahead of print. PMID: 34450472.


High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. 

Herring AA, Vosooghi AA, Luftig J, et al. 

JAMA Netw Open. 2021;4(7):e2117128. doi:10.1001/jamanetworkopen.2021.17128


Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. 

Adams KK, Machnicz M, Sobieraj DM. 

Addict Sci Clin Pract. 2021 Jun 8;16(1):36. doi: 10.1186/s13722-021-00244-8. PMID: 34103087; PMCID: PMC8186092.


Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. 

Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B. 

Patient Prefer Adherence. 2021 Jun 14;15:1259-1267. doi: 10.2147/PPA.S311674. PMID: 34163143; PMCID: PMC8214559.


Advancing emergency department-initiated buprenorphine. 

Huntley K, Einstein E, Postma T, Thomas A, Ling S, Compton W. 

J Am Coll Emerg Physicians Open. 2021 Jun 16;2(3):e12451. doi: 10.1002/emp2.12451. PMID: 34179878; PMCID: PMC8208651.